Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric RRMS study of Tecfidera versus Avonex with optional open-label extension
MOH_2017-08-01_000693Phase 3Completed
- Sponsor
- Biogen
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dimethyl fumarate in multiple sclerosis (MS) (3 arms), sponsored by Biogen. Primary endpoints: Safety and tolerability of BG00012 in Part 1, Effect of BG00012 on disease course in Part 1 and 3 more. Started Nov 2015; status: completed.
02
Drugs
dimethyl fumarate
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on MOH_2017-08-01_000693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-08-01_000693.